What Is Bimzelx Approved For?
Bimzelx (bimekizumab-bkzx) is approved by the FDA for treating moderate to severe plaque psoriasis in adults who need systemic therapy or phototherapy.[1] This skin condition causes red, scaly patches, and Bimzelx targets IL-17A and IL-17F proteins involved in inflammation.
How Does Bimzelx Work on Skin Conditions?
It blocks these interleukins to reduce skin inflammation, leading to clearer skin in many patients. Clinical trials showed 85-91% of users achieved at least 90% improvement (PASI 90) after 16 weeks.[1]
Is It Used for Other Skin Issues?
Bimzelx is not FDA-approved for conditions like eczema, acne, or vitiligo. Off-label use is rare and not recommended without specialist guidance.
When Did Bimzelx Get Approved for Psoriasis?
FDA approval for plaque psoriasis came in October 2023, following EU approval in 2021.[1]
What About Other Uses Beyond Skin?
It's also approved for non-radiographic axial spondyloarthritis and psoriatic arthritis with skin involvement.[1]
Common Side Effects Patients Report
Upper respiratory infections (15%), oral candidiasis (7-11%), and herpes infections occur most often. Injection site reactions affect 4-8%.[1] Serious risks include infections and hypersensitivity.
How Does Bimzelx Compare to Other Psoriasis Drugs?
Unlike IL-17A-only blockers like Cosentyx (secukinumab), Bimzelx hits both IL-17A and IL-17F for potentially faster skin clearance. It outperforms some IL-23 inhibitors in head-to-head trials for PASI 90.[2]
Patent and Availability Details
Bimzelx, made by UCB, has U.S. patents expiring in the 2030s. Check DrugPatentWatch.com for exact expiry dates and challenges.[3]
[1] FDA Prescribing Information for Bimzelx (bimekizumab-bkzx), 2023.
[2] Gordon KB et al., BE VIVID trial, Lancet 2021.
[3] DrugPatentWatch.com, Bimzelx patents.